PUMA BIOTECHNOLOGY INC news, videos and press releases
For more news please use our advanced search feature.
PUMA BIOTECHNOLOGY INC - More news...
PUMA BIOTECHNOLOGY INC - More news...
- Puma Biotechnology Announces FDA Clearance of IND for Alisertib in Small Cell Lung Cancer
- Puma Biotechnology Reports Second Quarter Financial Results
- Puma Biotechnology to Host Conference Call to Discuss Second Quarter 2023 Financial Results
- Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
- Puma Biotechnology Announces Presentation of Biomarker Findings from a Phase II Study of Alisertib with Paclitaxel versus Paclitaxel Alone in Metastatic or Locally Recurrent Breast Cancer at the 2023 ASCO Annual Meeting
- Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
- Puma Biotechnology Reports First Quarter Financial Results
- Puma Biotechnology to Host Conference Call to Discuss First Quarter 2023 Financial Results
- Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
- Puma Biotechnology Announces Publication of Phase II Clinical Trial of Alisertib in JAMA Oncology
- Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
- Puma Biotechnology Reports Fourth Quarter and Full Year Financial Results
- Puma Biotechnology to Participate in a Panel Discussion at Cowen’s 43rd Annual Health Care Conference
- Puma Biotechnology to Host Conference Call to Discuss Fourth Quarter and Full Year 2022 Financial Results
- Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
- Puma Biotechnology’s NERLYNX® Included in NCCN Clinical Practice Guidelines for the Treatment of Breast Cancer with a HER2 Mutation
- Puma Biotechnology to Present at B. Riley Securities’ 3rd Annual Oncology Conference
- Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
- Puma Biotechnology Releases Updated Corporate Presentation
- Puma Biotechnology Presents Updated Findings from the TBCRC-022 Trial at the 2022 San Antonio Breast Cancer Symposium
- Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
- Puma Biotechnology Reports Third Quarter 2022 Financial Results
- Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
- Puma Biotechnology Presents Updated Findings from the Phase II SUMMIT Basket Trial of Neratinib in EGFR Exon 18-Mutant NSCLC at the 2022 EORTC/NCI/AACR Symposium
- Puma Biotechnology to Host Conference Call to Discuss Third Quarter Financial Results
- Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
- Puma Biotechnology Announces Exclusive License Agreement with Takeda for the Development and Commercialization of Alisertib, an Investigational Aurora Kinase A Inhibitor
- Puma Biotechnology Presents Updated Findings from the Phase II SUMMIT Basket Trial of Neratinib for HER2-Mutant, Recurrent/Metastatic Cervical Cancer at the ESMO Congress 2022
- Puma Biotechnology to Present at the H.C. Wainwright 24th Annual Global Investment Conference
- Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)